Recombinant Anti-CD89 x Anti-EGFR Bispecific Antibody (scFv4-Ig) is an appended IgG format, which includes four scFv moieties at the N-termini of the constant regions. It is a bivalent homodimer, in which one anti-CD89 scFv is fused to the CH1 domain of a heavy chain and another anti-EGFR scFv to the CL domain of a light chain, or vice versa. The resulting leads to 2+2 antigen-binding valency. This BsAb can retarget macrophages to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Non-small cell lung cancer (NSCLC); Solid tumors therapy.